1344707-44-3

Upstream product

• 1344708-40-2 (R/S)-ethyl 2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1344708-39-9 (R/S)-(E/Z)-ethyl 2-hydroxy-2-(4-(N'-hydroxycarbamimidoyl)phenyl)acetate 
• 847227-46-7 ethyl 2-(4-cyanophenyl)-2-hydroxyacetate 
• 1236188-83-2 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride 
• 1236188-80-9 3-phenyl-4-(trifluoromethyl)isoxazole-5-carboxylic acid 
• 1236188-79-6 (3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)methanol 
• 154016-48-5 (5-methyl-3-isoxazolyl)methylamine 
• 1344708-41-3 (R/S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 
• 932-90-1 syn-benzaldehyde oxime 
• 302912-31-8 ethyl-4-cyanobenzoylformate 
• 934-16-7 phenylhydroxamoyl chloride 

Relevant academic research and scientific papers

4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.